United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Pharma Industry News Be Biopharma reports positive preclinical data for BE-102 in hypophosphatasia Be Biopharma shares preclinical results for BE-102, a B cell medicine in development for treating hypophosphatasia. Read about its novel approach. byPallavi MadhirajuMay 18, 2025